Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today announced that the Company will present one-year, safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD) at this year’s Parent Project Muscular Dystrophy (PPMD) Annual Conference.
The details are as follows:
Dr. Linda Marbán, CEO, will present the one-year open label extension results via a late-breaking session on June 25, 2022, at 5:05 p.m. MT.
Capricor will also deliver a clinical update as part of PPMD’s “Novel Approaches for Combatting Duchenne” session on June 25, 2022, at 11:00 a.m. MT.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.